Butler flags national oversight concerns as pharmacy prescribing expands

6 minute read


The minister says state-led expansions of pharmacy prescribing are moving so quickly that national authorities are struggling to keep pace, prompting discussions about a more consistent regulatory framework.


Federal health minister Mark Butler has acknowledged that rapidly expanding pharmacy prescribing arrangements across Australia are proving difficult for national authorities to keep pace with, revealing discussions among health ministers about the need for a more coherent regulatory framework. 

Speaking at the RACGP’s GP26 conference in Adelaide this morning, Mr Butler said scope-of-practice reforms were progressing at very different speeds across jurisdictions, particularly in pharmacy prescribing. 

“This thing, particularly in the pharmacy space, is moving at very different paces, usually quite quick at a state level, with states making changes to their state arrangements that we are frankly having a little difficulty keeping abreast of,” he said. 

“It’s changing so quickly.” 

Mr Butler said health ministers had discussed the need for greater consistency in the regulatory approach to expanded scopes of practice. 

“We have had a discussion with health ministers about the need, frankly, to have a little more of a coherent framework for boards to adhere to as they are stepping through some of these proposals,” he said. 

He acknowledged concerns within the medical profession about the quality and safety of care under expanded prescribing arrangements, while recognising arguments about improving patient access. 

“I completely understand that there is concern about this in the medical community and not just from a territorial perspective, from a quality care perspective,” he said. 

However, he pointed to access to treatment for uncomplicated urinary tract infections on weekends as an example of the potential benefits. 

Public evaluation promised 

Mr Butler also committed to a thorough, publicly available evaluation of the National Women’s Health Trial, which covers pharmacist prescribing for uncomplicated urinary tract infections and contraception. 

Asked by newly elected RACGP president Dr Ramya Raman whether he would commit to a clinically robust, independent and publicly available evaluation, as recommended by the Grattan Institute and called for by the RACGP, Mr Butler replied: “Yes.” 

The response drew sustained applause from the GP-laden audience. 

He said the trial was limited to 12 months and essentially provided a payment arrangement for services already available under state prescribing arrangements. 

“And yes, I’m very, very much committed to a thorough evaluation, which will be public,” he said. 

While he committed to a public evaluation, Mr Butler did not explicitly confirm whether it would be independently conducted. 

He also pointed to the recently legislated registered nurse endorsed prescribing model as an example of how scope-of-practice reforms could be developed with broad professional support. 

Mr Butler described that model, which he said had been developed over approximately a decade, as the “gold standard” because of the consensus achieved, including among medical stakeholders.

Expanded GP scope considered to tackle specialist fees 

The minister also raised the prospect of expanding GPs’ scope of practice as part of efforts to address rising out-of-pocket costs for non-GP specialist services. 

He said patients’ out-of-pocket payments for non-GP specialist care had approximately doubled over the past seven years, with substantial variation in charges between practitioners. 

According to Mr Butler, around 1.5 million out-of-pocket charges were between three and five times the average charged by specialists’ colleagues, while 220,000 procedures annually attracted charges more than five times the average. 

“That is difficult to explain. That is difficult to rationalise,” he said. 

Mr Butler said the government was considering referral arrangements and ways to introduce greater competition into parts of the specialist sector. 

“There’s a lot of work that’s preserved to non-GP specialists that GPs could very rightly be doing if they choose to,” he said. 

He said he wanted further discussions with the RACGP about the possibility. 

Independent Medicare pricing remains on the table 

Mr Butler also declined to rule out independent pricing of Medicare services, pointing to existing arrangements in hospitals and aged care and his willingness to consider a similar model for the NDIS. 

Dr Raman questioned whether Medicare rebates should be determined by an independent pricing authority, arguing that this year’s 2.6% indexation increase was below CPI and healthcare inflation. 

Mr Butler acknowledged that independent pricing would represent a substantial policy and budgetary shift. 

“That would be a big step,” he said. 

“It would not be unprecedented in my portfolio.” 

He cited activity-based hospital funding and the introduction of independent aged-care pricing, which takes account of wage movements and the cost of delivering care. 

“We’ve not made a final decision about this, but we have, and I have indicated some willingness to move down an independent pricing model for NDIS as well,” he said. 

“I don’t want to say never,” he added. 

Mr Butler said he had not yet received final advice on the work undertaken with the sector and department, but welcomed further discussion despite the substantial budget implications. 

AI regulation under growing pressure 

Mr Butler also acknowledged the pressure that rapidly advancing artificial intelligence was placing on healthcare regulation, particularly the Therapeutic Goods Administration. 

He said a whole-of-government examination of the suitability of existing AI regulatory arrangements had identified the TGA as one of the stronger regulators. 

However, he warned that the pace and complexity of AI development would challenge even established regulatory systems. 

“There’s no question that the speed and the complexity of this technology is going to place pressure on the TGA as well as others, so we’re watching that very closely,” he said. 

Mr Butler identified clinical documentation and diagnostics as areas offering significant opportunities, subject to appropriate safeguards. 

He acknowledged recent debate over AI scribes and said he was keen to hear GPs’ views on the balance between innovation and regulation. 

He also expressed concern about young people using AI chatbots for psychological support, questioning whether they were turning to the technology because other options were unavailable. 

“I don’t want AI to become the easy answer anywhere,” he said. 

“Most importantly in healthcare, I don’t want it to become a substitute for good human to human contact and support and care.” 

End of content

No more pages to load

Log In Register ×